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 Biologically active naturally produced and synthetic compounds often feature 
chiral centers and heteroatoms. The inclusion of these heteroatoms in cyclic motifs such 
as lactones and lactams with specific stereochemistry is common.  While naturally 
produced compounds can be isolated, often the small quantities that can be collected 
are not sufficient for extensive testing or commercial production. This yield issue can be 
overcome by total synthesis of the natural compound. Additionally, the total synthesis of 
complex bioactive compounds allows for the derivatization of the structure, which can be 
used to improve efficacy or better understand the mechanism of action. To effectively 
produce natural products efficient methodologies for enantioselectively synthesizing 
complex motifs, such as spirocycles and bicycles, are needed.  
The research described in this thesis applies the asymmetric synthetic method of 
desymmetrization to the synthesis of enantioenriched bicyclic and spirocyclic motifs. The 
symmetric achiral starting materials for both projects are synthesized and then reacted 
with chiral phosphoric Brønsted acid catalysts to cause enantioselective intramolecular 
cyclization. While the attempts to form the bicyclic lactone have yet to produce 
detectable desired product, the work done has shown the ability to synthesize starting 
materials and given insight into possible productive modifications. The spirocyclic work 
has expanded the substrate scope started previously in the Petersen group and sets the 
foundation for a mechanistic pathway study for the spirocyclic formation. The application 
of the desymmetrization methodology to an increasing number of symmetric substrates 
explores the wide scope of this reaction mechanism. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Chirality 
The discovery and synthesis of small molecules with biological activity is a major 
focus for many branches of chemistry. While the structure of such molecules can vary 
widely, there are certain aspects which play a large role in many bioactive compounds; 
the presence of heteroatoms and chiral centers are two such aspects. Asymmetric 
centers particularly result in a variety of synthetic difficulties and complex biological 
activity effects. A traditional chiral center is an atom with 4 differing substituent groups 
and the fixed geometric configuration of these groups will determine the activity of that 
center or compound. Each chiral center has a nonsuperimposable mirror image which 
represents the opposite configuration of those same groups. When configurations of all 
of these stereocenters are reversed the corresponding compound is the enantiomer, 
while if some, but not all, of the configurations are changed the resulting molecule is a 
diastereomer of the original. Diastereomers are chemically inequivalent, meaning they 
can be distinguished and separated in achiral environments. Conversely, enantiomers 
are chemically equivalent in achiral environments and only possess differing activity 
when interacting with a chiral agent, making them much more difficult to purify or 
synthesize enantioselectively. The geometric conformation of the molecule can have a 
dramatic effect on the way it interacts with biological systems due to the fact that the 
majority of enzymes and active sites which bind to the small molecule are chiral in 
nature. Due to the differing activity of diastereomers or enantiomers of the same 
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compound, the synthesis of enantioenriched motifs and compounds is of great 
importance in the production of drugs.  
 
 
Figure 1. Enantiomers of Ethambutol 
 
 
The compound ethambutol (Figure 1) features both aspects, as well as 
highlighting the potential danger of using a mix of enantiomers in vivo. The activity of 
ethambutol against tuberculosis was first discovered in 1961 by J.P. Thomas and 
coworkers during a screen of synthesized small molecules.1,2 While this initial activity 
study identified D-ethambutol (1) as the enantiomer responsible for most of the 
therapeutic effects, the toxicity of L-ethambutol (2) was not established and so the more 
easily synthesized racemic mixture was used for the initial clinical trials.1,2 These clinical 
trials, reported by Carr and Henkind, resulted in serious toxic ocular symptoms, causing 
blindness or severe visual impairment in nearly half of the patients.2,3 Given these 
damaging side effects, the enantiomers were separated and the therapeutic D-
ethambutol was used in subsequent trials.2 Through multiple studies of the D-enantiomer 
it was determined that the toxicity was predominantly due to the L-ethambutol, and so D-
ethambutol was used as a single enantiomer.2,4,5 There is still debate over the toxicity of 
D-ethambutol, specifically the severity and occurrence of the ocular side 
effects reported, but it is undoubtedly to a lesser degree than the racemic mixture.5 
The selection for enantiopure forms of a compound not only applies to synthetic 
small molecules, but natural products as well. While a wide number of compounds 
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isolated from natural sources demonstrate biological activity, the purification process of a 
single compound from an extract can be tedious and difficult, with a complex mixture of 
compounds often present. Additionally, the yield of a single compound from an extract 
can be extremely small, requiring a large quantity of natural material to produce a usable 
amount of the desired compound. One method to circumvent this issue is the 
semisynthesis of a compound, using a more abundant natural product precursor as 
starting material.6 This approach greatly shortens the synthesis of a complex natural 
product while requiring a much more reasonable amount or type of biomass. Another is 
total synthesis, which uses commercially available compounds to synthesize the natural 
product. While this method can be lengthy, it also gives complete synthetic control over 
the molecule and does not rely on any biological source. 
 
 
Figure 2. Natural Product Ecteinasciden 743  
 
 
Isolated from the colonial tunicate Ecteinascidia turbinata in 1986, ecteinascidin 
743 (Figure 2) is one biologically active natural product which greatly benefitted from a 
semisynthesis approach.6,7 Now known by the pharmaceutical name Yondelis, 
ecteinascidin 743 is the most abundant of six ecteinascidin compounds isolated from the 
same colonial tunicate with a yield of 0.0001%.6,7 Although it demonstrated great activity 
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against leukemia cell lines with an IC50 of 0.5 ng/mL, the extremely low yield restricted 
ecteinascidin 743 from extensive biological activity testing.6,7 Initially a total synthesis 
was designed by Corey et. al. which took a total of 13 steps and produced derivatized 
analogs which also displayed biological activity, though the original compound remained 
the most potent.8,9 This synthesis allowed greater access to the natural product, but was 
improved upon by using cyanosafracin B (5), a fermentation product of the bacteria 
Pseudomonas fluorescens which can be harvested for starting material on a kilogram 
scale.9 This semisynthesis is completed in 10 steps, still allowing for derivatization, and 
has enabled the large scale production of ecteinascidin 743.6,9 With availability no longer 
an issue, ecteinascidin 743 moved on to extensive clinical trials, eventually making it 
onto the drug market as Yondelis.6 
 
 
Figure 3. Starting Materials for the Total and Semisynthesis of Ecteinascidin 743 
 
 
As with many natural products, ecteinascidin 743 exists as a single enantiomer, 
and so its  total synthesis required the application of enantioselective synthetic 
techniques.8,9 While the total synthesis was later improved upon by the use of naturally 
made complex starting material, the ability to synthesize ecteinascidin 743 allowed for 
continued biological testing and derivatization.8,9 The semisynthesis of ecteinascidin 743 
decreased the number of steps and the complexity of the process due to the numerous 
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stereocenters already set in the natural precursor cyanosafricin B. As shown in Figure 3, 
cyanosafricin B possesses 6 of the 8 stereocenters of the final product ecteinascidin 
743, while the starting material (4) made in 1 step from commercially available 
compounds for total synthesis possesses none. Thus, both biologically active 
compounds discussed serve as clear examples of the need for facile, diverse 
enantioselective synthetic strategies. 
1.2 Asymmetric Synthesis Strategies 
To produce enantioenriched materials for novel small molecules or the total 
synthesis of natural products, asymmetric synthetic techniques are vital and expanding. 
While there are many varied approaches to this task, kinetic resolutions and 
desymmetrizations are two major types. 
1.2.1 Kinetic Resolution  
 
 
Figure 4. General Schematic of Kinetic Resolution 
 
 
The strategy of kinetic resolution is an important option for enantioselective 
synthesis. The term includes an array of specific variations allowing for its wide 
applicability, but all incorporate the same basic methodology.10,11 The basis of all kinetic 
resolutions is shown in Figure 4; the exposure of racemic starting material (SM) to a 
chiral agent allows for the separation of the starting material enantiomers (SMR and SMs) 
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due to the difference in the rates of the reaction (kR and kS) to form the product (P).10,11 
The difference in the activation energies for the two enantiomers at the rate determining 
step (ΔΔG‡) is used to determine the relative rates of reaction, and, therefore, which 
enantiomer will be converted to the product more quickly. This rate disparity allows for 
the ideally complete conversion of one enantiomer of starting material to product before 
the other enantiomer, producing both enantioenriched product of the faster enantiomer 
and enantioenriched starting material of the slower. The degree of selectivity or 
difference in reaction rates for the two enantiomers of starting material is expressed by 
the selectivity factor (s). As shown in Figure 4, the selectivity factor is the ratio of the kfast 
to kslow, a larger number indicating a larger rate difference.10,11 This value allows for the 
comparison of kinetic resolutions using differing substrates and reactions based on 
stereoselectivity and energy difference.10,11 Ideally, this method can produce the faster 
reacting enantiomer product and the slower reacting enantiomer recovered starting 
material in up to 100% enantiomeric excess and 50% yield for each, considering the 
initial racemic mixture contains 50% of each enantiomer. Overall the yield of 
enantioenriched material is up to 100%, and the enantioenriched starting material could 
be converted to enantioenriched product in a subsequent reaction. The benefits of this 
method are its versatility, and ability to be applied in combination with other 
enantioselective synthetic techniques, with the maximum of 50% yield of 
enantioenriched product its main detriment.10,11 
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1.2.2 Desymmetrization 
 
 
Figure 5. General Schematic of Desymmetrization 
 
 
Desymmetrization is a method of enantioselective synthesis which, unlike kinetic 
resolution, can produce products with up to 100% yield and 100% enantiomeric excess. 
The basis of this difference is the achiral nature of the starting material, which features 
two enantiotopic groups at the prochiral center and a plane of symmetry (Figure 5). 
When the starting material interacts with the chiral catalyst, one of the enantiotopic 
groups is altered, resulting in the establishment of a chiral center. Similar to kinetic 
resolution, the enantioselectivity of this transformation is established by a rate difference, 
in this case between the 2 different configurations the prochiral starting material can 
form when interacting with the chiral agent. Due to the absence of chirality in the starting 
material, there is the potential for all the starting material to be converted through the 
favorable interaction (kfast) to enantioenriched product.   
1.3 Organic Chiral Brønsted Acid Catalysts 
The use of organic compounds to catalyze asymmetric synthesis is often 
preferable to the metallic and enzymatic alternatives for many reasons. While metal 
catalysts require inert storage and careful handling to avoid deactivation, 
organocatalysts can often be stored in non-inert conditions.12,13 The generally lower 
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prices as compared to metal catalysts for many organocatalysts is another benefit, as 
well as the more environmentally friendly nature of the carbon-based catalysts.12,13 
Handling difficulties apply not only to metallic but enzymatic catalysts as well.13,14 In 
addition, enzymatic catalysts often suffer from limited versatility and difficulty in 
recovery.13,14 These factors have led to a dramatic increase in organocatalytic usage and 
development in recent years.12,13,15–17    
 
 
Figure 6. Chiral Hydrogen Bonding and Brønsted Acid Organocatalysts 
 
Within this growing field of chiral organocatalysis is the branch of chiral Brønsted 
acid catalysts. As one of the most newly developed branches, the popularity and 
development of chiral Brønsted acid catalysts was first spurred by the 2004 application 
of chiral BINOL phosphoric catalysts to Mannich type reactions by the Akiyama and 
Terada groups.18–20 Since then, Brønsted acid catalysts have been applied to a variety of 
asymmetric reactions and the diversity of catalyst structure and acidity allows for wide 
scope of applications.15–17,20,21 Examples of commonly used Brønsted acid catalysts are 
based on a TADDOL (6), camphor sulfonic acid (7), thiourea (8), or BINOL phosphoric 
acids (9-12) scaffold (Figure 6). 
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1.4 Previous Work in the Petersen Group 
 
 
Figure 7. Kinetic Resolution of α-Hydroxy Esters 
 
 
The cumulative work done over previous years by members of the Petersen 
group has utilized each of the discussed asymmetric synthesis concepts. In 2013 the 
synthesis of enantioenriched hydroxy esters (13) through kinetic resolution was reported 
(Figure 7).22 This method used the aryl-substituted BINOL phosphoric acid TRIP catalyst 
(12) to enantioselectively cyclize hydroxy esters to their corresponding lactones, 
producing enantioenriched hydroxy ester and lactone products.  
 
 
Figure 8. Synthesis of Enantioenriched Monocyclic Lactones via Desymmetrization 
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A paper published in 2014 utilized the same BINOL-derivative phosphoric acid 
catalyst to complete the desymmetrization of prochiral diesters (15a-15g) to 
enantioenriched lactones (16a-16g).23 The substrate scope of this work, shown in Figure 
8, featured the synthesis of compounds incorporating a variety of substituents, including 
alkyl, aryl, and allylic groups, in good to great yields and enantiomeric excess.23 This 
more recent publication served as the direct precursor to the desymmetrization work 
discussed in the following chapters. In both the desymmetrization and kinetic resolution 
the activation of the BINOL phosphoric acid catalyst involves both acidic and basic 
coordination (Figure 9). The  carbonyl oxygen of the substrate is activated through 
hydrogen bonding or full hydrogen transfer of the catalyst’s hydroxyl hydrogen, while the 
hydroxyl group of the substrate coordinates similarly to the double bonded oxygen of the 
catalyst. This double activation encourages the intramolecular nucleophilic attack at the 
carbonyl carbon at both the nucleophilic and electrophilic groups. This attack forms the 
lactone product and causes the compound to dissociate from the catalyst. The BINOL 
catalyst’s axial chirality and large, bulky substituents enantioselectively direct the 
cyclization reaction.15,22,23 Our hypothesis is that the enantiomer or configuration with 
less steric clashing between reactant and chiral substituents will bind more favorably to 
the catalyst, with that enantiomer then progressing to enantioenriched product.  
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Figure 9. Proposed Activation of BINOL Catalyst 
 
 
1.5 Conclusion 
 
The work discussed in the following sections will seek to utilize the 
desymmetrization method of asymmetric synthesis to produce compounds containing 
all-carbon chiral centers enantioselectively. These investigations will expand on the 
previous work done in the Petersen lab and further explore the applications of chiral 
Brønsted acid catalyzed desymmetrizations. The successful synthesis of meso starting 
material for bicyclic and spirocyclic lactone formation is detailed, as well as attempts to 
produce the desired enantioenriched compounds.  
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CHAPTER II 
ASYMMETRIC SYNTHESIS OF ENANTIOENRICHED BICYCLES 
 
2.1 Introduction 
 
  
Figure 10. Natural Product Jujuboside B 
 
 
Bicyclic lactones and ethers are motifs found in a variety of biologically active 
natural and synthesized compounds. Compounds 17 and 19, found in Figures 10 and 
11, are two examples of complex molecules containing this motif and demonstrate the 
wide-reaching applications. Jujuboside B (17) is a natural product extracted from the 
mature seed of Zizyphus jujube Mill of Rhamnaceae, Zizyphi Spinosi Semen (ZSS).24 
The dried seed has been a part of traditional Chinese medicine for centuries, used to 
treat conditions for amnesia to insomnia, and containing a variety of active compound 
families such as flavonoids, alkaloids, and jujuboside B’s family, saponins.24,25 Extracted 
and elucidated by x-ray crystallography in 1978, jujuboside B is one of the major 
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sapoinins contained in ZSS and has shown biological activity as an isolated compound 
toward tumor formation suppression and vascular tension reduction, the latter a benefit 
which has only recently been investigated in depth.24,25  
 
 
Figure 11. Natural Product Suksdorfin and Synthetic Derivative DCK 
 
 
Compound 19, 3’,4’-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK), is a synthetic 
analog of the natural product suksdorfin (18), derivatized due to the original compound’s 
high activity in HIV-1 replication inhibition.26 As shown in Figure 11, DCK maintains 
suksdorfin’s core structure while substituting alkyl chains for bicyclic lactone motifs, a 
change which decreased the EC50 from 1.3 µM to 0.00041 µM.26 Following this initial 
total synthesis in 1994 there have been numerous publications focused on the synthesis 
of derivatives of DCK, altering each of the components of the molecule to determine the 
importance of each.27 In addition to determining the large difference in reactivity of the 
diastereomers,  the inclusion of at least one bicyclic lactone motif in the compound 
proved to be critical to the bioactivity.28–30    
 Despite their demonstrated biological activity and applications in synthetic 
analogs, current methods to synthesize bicyclic esters and lactones are limited. This 
limitation is no doubt due to the motif’s inherent steric bulk and ring strain, with 
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substitution increasing the steric difficulties and increasing the number of asymmetric 
centers. In the wide synthetic substrate scope of DCK derivatives completed since its 
discovery the bicyclic lactone motif was only added onto the periphery of the molecule 
using commercially available (S)-(-)-camphanoyl chloride, never synthesized.27–30 While 
the availability of this bicyclic reagent is extremely useful, it can only be used to add the 
bicyclic motif in specific circumstances. The lack of bicyclic synthesis in the DCK-based 
substrate scope speaks to the difficulty of the component’s synthesis, especially given 
the motif’s established biological activity importance and the numerous derivatizations of 
other motifs.27–30  
 The synthesis of such bicyclic motifs is highly limited in the variety of reagents 
that can be used. Many of the published procedures are base catalyzed, some using 
strong bases such as sodium hydroxide.31,32  While this approach works for simple 
compounds, the ability to apply it to more complex molecules, especially those with 
base-sensitive motifs, is a severe hindrance. Other common methods include the use of 
metal catalysts, whose detriments have already been discussed in Chapter 1,33,34 or 
radical initiators.35 As shown in the DCK studies, camphanoyl chloride can be used to 
add the motif to a nucleophilic center, but this approach requires an appropriately active 
atom with minimal steric hindrance to complete. The addition of camphanoyl chloride 
also does not allow for the integration of the bicyclic motif into the core of the structure. 
Along with the logistical limitations of many of these common methods, producing 
compounds with enantioenriched substitution at a non-bridgehead carbon is a difficulty, 
often producing a mix of diastereomers.33,35  These restrictions encouraged us to work 
toward the development of a new, acid-catalyzed synthetic method. 
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Figure 12. Desymmetrization of Meso Diesters to Enantioenriched Bicycles 
 
The general approach outlined in this thesis for the formation of enantioenriched 
bicyclic lactones is the desymmetrization of monocyclic, meso diesters (20) to bicycles 
(21) through a single step as shown in Figure 12. This transformation includes the use of 
a chiral phosphoric Brønsted acid catalyst to set all 3 of the asymmetric centers of the 
resulting bicycle, producing enantioenriched compound 21. This approach aims to take 
advantage of the knowledge gained by previous desymmetrization research in the 
Petersen group with meso diesters and expand the applicability of the methodology.        
2.2 Results and Discussion 
 
 
Figure 13. Overall Synthetic Pathway for Enantioenriched Bicyclic Lactones 
 
 
 The overall synthetic scheme for the synthesis of meso cyclopentyl diesters such 
as 20 and their desymmetrization to bicycle 21 is shown in Figure 13. To begin, the 
succinic anhydride portion on cyclohexene 22 is opened in acidic conditions, to produce 
dicarboxylic acid cyclohexene 23.36 The dicarboxylic acid then is esterified with a variety 
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of alcohols in acidic conditions to yield diester 24.37 The cyclohexene of the diester is 
then opened, converting the alkene to a dicarboxylic acid, 25, with the use of potassium 
permanganate.38 Cyclization of 26 into a five-membered cyclic diester lactone 26 is 
accomplished using acetic anhydride and sodium acetate.38 This lactone is reduced to 
an alcohol, 20, with the use of sodium borohydride before the final chiral Brønsted acid 
catalyzed cyclization of the compound to enantioenriched bicycle 21. 
 
 
Figure 14. Opening of Succinic Anhydride Ring 
 
 
The initial synthetic step of opening the succinic anhydride ring of 22 to the 
dicarboxylic acid 23, shown in Figure 14, produced >99% desired product.36 The four 
diesters (27, 28, 29, and 30) were each synthesized utilizing the same general 
esterification method, shown in Figure 15.37 The methyl substrate was produced in the 
highest yield (70%) and the yields decreased as the alkyl group increased in steric bulk 
and size, with the ethyl, isopropyl, and tert-butyl esters being produced in 55%, 41%, 
and 20% yields, respectively. Given this yield and steric bulk considerations, the ethyl 
substrate (28) was chosen for further elaboration via the synthetic pathway described 
above, with the isopropyl substrate (29) carried through for comparison. 
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Figure 15. Esterification of Carboxylic Acid Motifs  
 
Cyclohexenes 28 and 29 were treated with potassium permanganate in water, 
resulting in the formation of dicarboxylic acids, 31 and 32 (Figure 16).38 Initially this 
conversion presented some challenges, as the consistency of the reaction solution made 
the extraction and washes difficult to complete. The addition of a large excess of acid 
before work up eliminated these difficulties and increased yields from 24% and 20% for 
the ethyl and isopropyl substrates respectively to >90% yields for both substrates without 
any purification required. 
 
 
Figure 16. Alkene Cleavage of Diesters 
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Cyclization of the dicarboxylic acid substrates 31 and 32 was done using sodium 
acetate and acetic anhydride under reflux to produce 33 and 34 in 54% and 35% yields 
respectively (Figure 17).38 This step’s yields suffered from the production of reaction 
byproducts as well as the necessity of purification, being the first synthetic step to 
require column chromatography. The nontrivial difference between the yield for the ethyl 
and isopropyl substrates in this step as in previous steps lead us to focus on the more 
reproducible ethyl compounds in future steps. 
 
 
Figure 17. Cyclization of Cleaved Product 
 
 
Before the key desymmetrization reaction could be attempted, cyclic ketone 33 
was reduced to the alcohol 35, using sodium borohydride in ethanol (Figure 18). As 
suggested in the representation of compound 35, the confirmation of the alcohol 
stereocenter is not known. The steric bulk caused by the cis-diesters would suggest that 
the hydride would add to the ketone carbon from the opposite side of the molecule, 
forming the desired all cis diastereomer. The formation of this diastereomer could be 
confirmed by NOESY 2D NMR, but initially the unidentified major diastereomer was 
simply collected. This step has yielded product 35 to varying degrees, as seen in Figure 
18, with yields ranging from a respectable initial yield of 69%, to yields of 35% and 22% 
in the most recent two attempts. The difficulty in completing this step with reproducible 
yields, compounded with the relatively long nature of the synthesis, has caused major 
setbacks in the ability to make bicyclization attempts. The reason for this yield decrease 
 
19 
 
has not been determined, as new sodium borohydride, longer reaction times, and higher 
temperatures have been applied to the reaction, resulting in no major yield 
improvements. The way in which the reaction is worked up may be one area for 
improvement, as initially the reaction mixture was simply filtered and dried, while recently 
a separation of water and organic layers was implemented. This change will be 
considered in future synthesis, as well as increasing the sodium borohydride 
equivalences and continuing to alter reaction conditions. 
 
 
Figure 18. Reduction of Cyclic Ketone 
 
 
With the starting material synthesized through the described five step pathway, 
the conversion of meso alcohol 35 to racemic bicycle 36 has been attempted in six 
combinations of reaction conditions and Brønsted acids (Figure 19). The two acids that 
have been attempted at this point are p-toluenesulfonic acid and camphor sulfonic acid, 
both of which were chosen because of their similarity of acidic activation to the chiral 
phosphate catalysts used in the Petersen lab to complete similar cyclizations, as 
discussed in Chapter 1. Unlike the phosphoric acid catalysts, these Bronsted catalysts 
do not have the capability to additionally base catalyze the substrate. The increased 
acidic strength of the compounds used in Figure 19 aims to overcome this activation 
discrepancy. p-Toluenesulfonic acid was used first in three different reaction conditions, 
most notably changed in temperature and time of reaction, with a variety of products 
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produced. Recovered starting material was consistently seen as the major result. The 
final most extreme conditions, reacting 35 with 0.5 equivalents of p-toluenesulfonic acid 
at 100oC, resulted in the addition of the acid into compound 35 at one of the esters and 
thus other acid catalysts were considered. D-Camphor sulfonic acid was a logical 
second choice, but once again none of the three different reaction conditions produced 
desired product 36, or at least not in large enough quantities to be isolated following 
column chromatography and identified by NMR.  
 
 
Figure 19. Racemic Cyclization Attempts to Form Bicycle 36 
 
2.3 Future Work 
The difficulties encountered in the synthesis of the current bicyclic targets has 
spurred the group to further analyze the synthesized starting material and consider new 
substrates. As mentioned, although the diastereomers of 35 were effectively separated, 
it is unknown whether the isolated major diastereomer is the necessary all-cis 
configuration. Due to the cis confirmation of the succinic anhydride in starting material 22 
and the lack of synthetic changes to either of the stereocenters in subsequent steps, the 
diesters of compound 35 are assumed to be cis. If true, the only ambiguity of the overall 
configuration of compound 35 comes from the reduction of the ketone to the 
corresponding alcohol. As discussed, there was reasoning to suggest that the formation 
of the all-cis isomer would be more favorable based on steric bulk from the diesters. As 
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the all-cis is the diastereomer which could have most readily cyclized, successful 
production of bicycle 36 would have suggested the isolation of the all-cis diastereomer of 
compound 35. The inability to form the bicycle could, therefore, be caused by the 
isolation and reaction of a trans diastereomer or the actual incapability of the all-cis 
diasteromer to cyclize. To determine whether compound 35 is the all cis it will be 
analyzed by 2D NOESY NMR before further cyclization attempts. 
 
 
Figure 20. Possible Future Bicyclic Lactone Substrates 
 
 
Aside from the diastereomer concerns, the ring strain of the bicyclic structure 
may be a significant obstacle to its formation. In hopes to overcome this more 
fundamental difficulty, other compounds that may be explored in the future will feature 
an extension of the ester motifs from the ring. Figure 20 shows two possible new starting 
material substrates, 37 and 39, that could potentially produce slightly different bicyclic 
lactones (38 and 40). Both substrates, 37 and 39, maintain the same basic components 
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of the starting material, only altered by the inclusion of a carbon between the ring and 
the diester groups. Hopefully this addition will increase the favorability of the cyclization 
by both reduce ring strain and provide more free movement of the ester group, 
potentially allowing it to come closer to the alcohol. Additionally, by extending the ester 
chains instead of the alcohol moiety the overall achiral, meso nature of the compound 
remains intact.    
2.4 Conclusion 
 While the synthesis of the starting material has been completed, the 
enantioselective synthesis of the target bicyclic lactone substrates remains 
unaccomplished. The future directions discussed in the previous section are just several 
ideas for how this project may be adapted and further attempted, with a variety of alkyl 
chains in the diester as well as Brønsted acid catalysts that could still be explored. With 
the preliminary results collected, future investigation can be more accurately targeted 
towards more successful ends.
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CHAPTER III 
ASYMMETRIC SYNTHESIS OF ENANTIOENRICHED SPIROCYCLES 
 
3.1 Introduction 
 
 
Figure 21. Natural Products Glabratephrin and Yuccaol C 
 
 
The enantioselective synthesis of spirocyclic motifs featuring all carbon centers is 
both challenging and highly in demand. The difficulty of this process is due to the 
combined problems of carbon-carbon bond formation and setting an asymmetric center 
in high enantiomeric excess. Due to these challenges, the demand for synthetic 
techniques  remains, driven by the inclusion of the motif in many complex bioactive 
molecules. The natural products (+)–glabratephrin (41) and yuccaol C (42) are two such 
bioactive compounds (Figure 21). The herb tephrosia apollinea is native to Egypt and 
has produced compounds in a wide variety of natural product families, including 
rotenoids, isoflavones, flavanols, and flavonoid group, the final group including (+)–
glabratephrin.39,40 This myriad of compounds has shown biological activity in a variety of 
different ways, but the utility of flavonoids such as (+)–glabratephrin is predominately in 
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antifungal and antiparasitic applications.39,40 The synthesis of fully characterized natural 
compounds such as (+)–glabratephrin could lead to nontraditional synthetic agents, 
potentially circumventing biological resistance to known compounds and reducing the 
environmental impact of such crop treatments. Alternatively, the active compounds in 
yucca schidigera have been used in traditional Native American medicine as a complex 
extract for centuries, providing beneficial therapeutic instead of defensive effects.41,42 
The uses of the bark extract in traditional medicine have been widely varied, but 
following their identification the active compounds have particularly shown anti-
inflammatory and antioxidant properties.41–44 Yuccaol C is one of several similarly 
structured compounds found in the yucca extract, the structural family accounting for 
over half of the active compounds found in the bark.41  
 
 
Figure 22. Overall Synthetic Pathway for Spirocycles 
 
  
An overview of the basic synthesis of the spirocyclic compounds is shown in 
Figure 22. The starting compound, 43, is reacted with sodium hydride to form the 
enolate species, which nucleophilically attacks 44 to undergo a first alkylation. The 
specific structure of 44 will vary largely based on the substituents and size of the rings 
desired. The second alkylation from 45 to 47 is carried out in a similar method, using 
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sodium hydride to remove the remaining acidic hydrogen and initiate the substitution 
reaction. The removal of the selected protecting group on 47 yields a free alcohol in 48, 
which can then be enantioselectively cyclized via a desymmetrization with the chiral 
Brønsted acid TRIP to 49. The enantioenriched monocyclic lactone is converted to 
spirocycle 51 through the deprotection of the second protecting group, exposing the free 
alcohol in compound 50, followed by cyclization using an achiral catalyst such as p-
toluenesulfonic acid or trifluoroacetic acid 
The key features of this approach are the use of a chiral phosphoric Brønsted 
acid catalyst (12) with an achiral starting material (43) to produce the enantioenriched 
monocyclic lactone (49). The setting the central stereocenter in this step allows for the 
use of an achiral acid catalyst for the secondary cyclization to 51. The much lower cost 
and reaction time of the achiral catalyst makes this approach appealing for multiple 
reasons. Additionally, while unsubstituted oxygen-containing alkyl chains are shown in 
Figure 22, the inclusion of nitrogen and substituents have been demonstrated 
successfully, sparking interest into the range of applicability.   
3.2 Previous Work 
 
 
Figure 23. Spirocycles Included in Substrate Scope 
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The spirocyclic compounds included in the substrate scope of this project at this 
point are shown in Figure 23. The green compound 52 is the target of the preliminary 
work directly done and discussed in the following section. The synthesis of the blue 
compounds (56, 57, and 58) is in progress and is being worked on by other members of 
the Petersen lab, while the red, pink, and orange compounds (53, 54, 55, and 56) have 
been synthesized and characterized by Jennifer Wilent of the Petersen group. The 
orange compound, 53, is currently being resynthesized and recrystallized to obtain 
higher enantiopurity and crystals suitable for x-ray crystallography analysis. Compound 
54 in pink is the focus of a targeted synthesis to study the reaction pathway. 
 
 
Figure 24. Results for Completed Spirocyclic Compounds 
 
 
The preliminary spirocyclic work done by other members of the Petersen group 
has been extensive. Four compounds have been completed and two others have been 
started by Jennifer Wilent, the individual who initiated the project. The structures, 
percent yields, and enantiomeric excess of the completed compounds is provided in 
Figure 24. The completed substrates are the basis of this product. The spirocyclic ,-
bislactone 55 does not contain a traditional asymmetric center, but instead possesses 
axial chirality (Figure 25). Due to this absence of a traditional asymmetric center, which 
would contain four different groups, the precyclized starting material contains two 
enantiotopic groups, making the ability of the chiral Brønsted acid to cyclize 
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enantioselectively much more difficult. This lack of selectivity is the reason for the 0% 
enantiomeric excess. 
 
 
Figure 25. Depiction of Axial Chirality in Compound 55 
 
 
Compounds 53, 56, 57 and 58, shown in Figure 23, are currently being worked 
on in the lab. Compound 39 was completed by Jennifer Wilent, but is now being 
resynthesized as part of this project to improve the reported 80% enantiomeric excess 
by recrystallation. Amber Kelly is exploring the synthesis of 56 and continuing the 
synthesis of 57 begun by Jennifer Wilent with the assistance of Nick Chambers. The 
production of 58 has been started by Eni Minerali. The synthesis of the completed and 
unfinished compounds follows the same general synthesis pathway shown in Figure 22. 
3.3 Results and Discussion 
 3.3.1 Novel Substrate Synthesis 
 
 
Figure 26. Synthesis of Alkylating Agent 62 
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For spirocycle 52 a synthesis starting with 60 was required to produce alkylating 
agent 62, shown in Figure 26.45,46 First one of the alcohols of the diol 60 was converted 
to a tosyl group through a reaction with tosyl chloride and pyridine to produce 61.45 Next, 
the other alcohol was protected with an acetyl group when 61 was reacted with acetic 
anhydride and 4-dimethylaminopyridine to yield 62.46 Both conversions were completed 
in good yields, 82% and 90% respectively, although the tosylation required column 
separation to remove remaining starting material from the product. 
 
      
Figure 27. Attempted Alkylation using Compound 62 
 
 
With 62 synthesized, the previously described first alkylation to produce 
compound 63 was attempted (Figure 27). The position of the dimethyl carbon in 
compound 62 makes the substitution reaction more difficult, as an SN2 reaction is being 
attempted on a neopentyllic carbon. Initial attempts to perform this substitution have 
been unsuccessful with the tosylated compound 62, so an even better leaving group will 
be used to overcome the higher steric barrier. A mesylate group will be the first new 
leaving group tested, but iodide may be used if the mesylate compound is still 
unsuccessful. Both leaving groups have been used successfully in similar nucleophilic 
attacks of malonate compounds, 64 and 66 in Figure 28, at neopentyl carbons to form 
alkylated malonates, 65 and 67, in good yields.47,48 
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Figure 28. Literature Examples of Alkylation at a Neopentyl Carbon 
 
 
With this precedent in mind, the synthesis of the alkylating agent for the 
synthesis of spirocycle 52 was altered. The initial change was the replacement of the 
tosyl leaving group on compound 62 with a mesyl, a less sterically hindering and more 
readily removed group. To synthesize this mesyl derivative diol 60 was again mixed with 
pyridine in dichloromethane, but this time with methanesulfonyl chloride and at 0oC 
(Figure 29). The reaction proceeded successfully, producing the mesylated compound 
68, but extremely close Rf values between the desired product and side products made 
purification extremely difficult and so an accurate yield could not be determined. The 
somewhat purified product was further reacted with 4-dimethylaminopyridine, acetic 
anhydride, and triethylamine to protect the remaining alcohol group of 68 to yield 
compound 69 as shown in Figure 29. This transformation once again produced many 
side products which made purification by column chromatography necessary, but 
thankfully the Rf difficulties of the previous synthesis did not persist. The addition of 0.1% 
triethylamine to the chromatography solvent system helped to prevent the removal of the 
mesylate group by ensuring a nonacidic environment. Following purification, the desired 
product 69 was collected in an overall 37% yield.  
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Figure 29. Initial Synthetic Pathway for Compound 69 
 
 
To increase the overall yield for the synthesis of the alkylating agent 69, eliminate 
the purification difficulties encountered during the synthesis of compound 68, and reduce 
the number of steps in which the mesyl group needed to stay attached, the order of the 
alcohol group modifications was switched (Figure 30). To produce acetylated compound 
70 from diol 60 the latter was reacted with 4-dimethylaminopyridine, acetic anhydride, 
and triethylamine similarly to previous acetylations, but with the equivalence of acetic 
anhydride reduced from 1.7 to 1 to discourage diacetylation.  The reaction successfully 
produced the monoacetylated product 70 in 51% yield without separation difficulty. The 
mesyl group was then added to compound 70 using methanesulfonyl chloride and 
pyridine, now being able to use an excess of the mesylate reagent, but the production of 
side products and decreased the yield of the desired product.  
 
 
Figure 30. Alternative Synthetic Pathway for Compound 69 
 
 
Attempts to use compound 69 in an alkylation reaction with di-tert-butyl malonate 
to yield compound 63 were carried out with the same reagents but in differing reaction 
 
31 
 
environments and equivalences. The conditions and equivalences for these attempts are 
detailed in Table 1.  
 
Table 1. Reaction Conditions for Alkylation Attempts using Compound 69 
 
 
The first attempt mimicked the reaction conditions of alkylations performed 
previously in the Petersen group. The alternate reaction conditions were based off a 
similar neopentyl alkylation done by Liu et. al. and decreased the equivalences of all 
reagents and the temperature of reaction to room temperature rather than under reflux. 
Test reactions for these two sets of conditions were carried out simultaneously on small 
scale. Unfortunately, neither of these conditions yielded the desired product 63 in 
significant quantities. 
 
 
Figure 31. Synthesis of Compound 73 
Malonate 
equivalence 
NaH equivalence Alkylating agent 
equivalence 
Temperature 
conditions 
1 1.5 1 Reflux 
1 0.67 0.50 Room temperature 
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Due to the literature precedent of SN2 reactions occurring at centers neopentyl to 
a cyclopropane connecting carbon,48 investigation into the cyclopropane diol 71 
commenced. Much of the work to produce the alkylating agent 73 was run directly 
following the dimethyl substrate 69, and so the reactions and their order were nearly 
identical (Figure 31). The one major deviation from the dimethyl synthetic route was the 
discovery of an alternative acetylation procedure which could yield monoacetylated 72 in 
yields higher than 50% in a fraction of the time with very simplistic purification.49 This 
method was eventually applied to both substrates, giving a yield of 75% and 68% for the 
cyclopropyl and dimethyl diols respectively (Figure 31, 32). While this procedure 
improved the yield of the acetylation, the starting diol’s much higher cost has been a 
major synthetic constraint. Due to this, reactions were run on small scale, causing 
difficulties when side products were produced in the following mesylation step. The small 
scale, in addition to concerns of mesylate removal during column purification, resulted in 
the use of a crude mixture of 73 for the alkylation attempts. These attempts have yet to 
produce desired product in significant yields.  
   
 
Figure 32. Incorporation of Alternative Acetylation into Synthesis of Compound 69 
 
 
 
 
 
 
33 
 
 3.3.2 Synthesis and Recrystallization of Compound 53 
As shown in Figure 24, compound 53 was previously synthesized in 88% yield 
and 80% enantiomeric excess. While this enantioselectivity is good, we proposed the 
use of recrystallization to improve the enantiopurity and thus resynthesis of the substrate 
was required. The interest in obtaining a high enantiomeric excess for compound 53 is 
partially due to its lactone-lactam construction. Producing a lactone-lactam in similar 
enantiopurity to the lactone-lactone substrates would strengthen the applicability of the 
method to other core functional groups. Thus, compound 53 was resynthesized in efforts 
to produce a large quantity of material on which to attempt recrystallization to improve 
the compound’s enantiomeric excess.   
 
 
Figure 33. Enantioselective Cyclization of Compound 75 
 
 
The initial steps to resynthesizing 53 were started by Dr. Jennifer Wilent before 
her exit from the group. The work up of the first cyclization to compound 75 was the 
initial step following her involvement, and the yield from this step was only 35% (Figure 
33). This monocyclic product 75 was cyclized to spirocycle 53 as shown in Figure 34, but 
the small yield of the previous cyclization deemed a full additional synthesis necessary. 
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Figure 34. Cyclization of Compound 75  
 
The first steps of the synthesis (Figure 35) involve the dialkylation of 43 to 76, 
each alkylation using sodium hydride as the base to form the necessary enolate. The 
benzyl ether was added to the di-tert-butyl malonate in 72% yield, followed by the 
addition of N-tosylaziridine to produce compound 76 in 51% yield.  
 
 
Figure 35. Alkylation Steps to Form Compound 76 
 
The deprotection of the benzyl group from the oxygen was then completed by 
hydrogenolysis yielding compound 74, which was then be cyclized enantioselectively 
using TRIP catalyst to 75 (Figure 36). Unfortunately, the attempt to perform the second 
cyclization was slowed by contamination of the catalyst that lowered its reactivity. This 
was only realized after TLC analysis of the reaction progress and consultation with other 
group members. Due to this, the reaction was run for over 3 weeks and a second 
addition of the catalyst was added. The purification and yield determination for this 
cyclization are forthcoming.  
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Figure 36. Deprotection and Cyclization to Yield Compound 75 
 
 
 3.3.3 Reaction Pathway Study Synthesis 
 
 
Figure 37. Potential Pathways for Secondary Cyclization 
 
 
While the basic structure of the monocyclic and spirocyclic products can be 
determined through NMR and mass spectrometry, the absolute configuration of the two 
compounds cannot be derived from these two achiral analytical methods. For the 
configuration of the stereocenter to be determined, a chiral solvent can be used for NMR 
analysis, or a crystal structure of each of the compounds would be needed. Due to this 
lack of information, the pathway of second cyclization has yet to be determined. Figure 
37 shows the two potential cyclization routes from monocyclic 77 to spirocyclic 54. The 
first pathway, shown in red, features the attack of the tert-butyl ester by the free alcohol, 
resulting in the loss of tert-butoxide and the retention of stereochemistry at the central 
asymmetric center. Alternatively, the blue arrows show the attack of the lactone carbonyl 
by the alcohol, which would cause the subsequent opening and recyclization of the 5-
membered ring, inverting the stereochemistry of 54. 
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Figure 38. Planned Conversions to Compound 79 
 
 
To determine which of the previously discussed pathways accounts for the 
conformation of bicycle 54, compound 79 will be synthesized from 54 and 78 as shown 
in Figure 38. Compound 79 will be synthesized from the spirocyclic compound 54 via the 
attack of 4-bromobenzylamine at the carbonyl of the 6-membered lactone, resulting in 
the opening of the ring and formation of the amide in the product. The conversion of 
monocyclic 78 to compound 79 will use similar methods, but instead using the amine to 
attack at the ester position.50 The final step will be the removal of the protecting group on 
the alcohol, yielding 79. Attempts to crystallize the supply of 79 produced from each 
method will be made to determine the absolute configuration. The rotation of both 
compounds will also be measured using the polarimeter and compared. If the rotation of 
compound 79 produced from spirocycle 54 matches the rotation of the same compound 
synthesized from compound 78, the attack of the free alcohol at the lactone will be 
supported pathway. The opposite rotation will suggest the attack at the tert-butyl ester is 
the dominant pathway.    
 
 
 
 
37 
 
 
Figure 39. Initial Alkylation Reaction Sequence for Synthesis of Compound 80 
 
 
The use of directed synthesis to study the reaction pathway first requires the 
synthesis of the monocyclic and spirocyclic compounds. As shown in Figure 39, the first 
transformation uses sodium hydride to complete 2 alkylations, yielding product 80 after 
two steps. Previous syntheses done in the Petersen lab had done these in the order 
shown in Figure 39, with the larger benzylated alkylation agent added second. While this 
was successful in the past, current attempts to complete this synthesis required heat in 
the addition of this second alkylating agent and this caused the removal of the acetyl 
protecting group and the racemic cyclization to compound 78. To discourage this, the 
heat was lowered to room temperature and 40oC, but many side products and minimal 
desired product were produced in both cases. In hopes to alleviate these problems the 
order of the alkylating agents was reversed, now using the benzylated compound in the 
first step Figure 40). While there were separation difficulties between the monoalkylated 
intermediate and the benzyl alkylating agent, most of the benzyl alkylating agent is 
removed by the time the second alkylation is finished, allowing for easier separation.  
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Figure 40. Alternative Alkylation Sequence to Yield Compound 80 
 
 
Following the production of 80 the acetyl protecting group was removed using 
potassium carbonate to yield 81. The alcohol was then cyclized using TRIP (12) catalyst 
to yield 77, as shown in Figure 41. Due to the difficulties of the alkylating sequence the 
monocyclic product has only been isolated is minor yields, but with the sequence effects 
now resolved this should be improved upon.       
 
 
Figure 41. Deprotection and Cyclization to Yield Compound 77 
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3.4 Future Work 
 
 
Figure 42. Potential Future Spirocyclic Substrates 
 
While difficulties have been encountered in the synthesis of the attempted 
alkylating agent and spirocyclic substrate, investigation into several new alkylating 
agents has already begun. The iodide leaving group is still an unexplored avenue for the 
successful production of compound 52, but its incorporation can be even more 
problematic than that of the mesylate. Due to this remaining difficulty, alternative 
substrates 84-90  shown in Figure 42 are being considered. Alkylation to obtain these 
new compounds would no longer involve performing an SN2 reaction at a neopentyl 
carbon, presumably the main source of synthetic difficulty. The compounds 84-90 are an 
expansion of the substitution in compound 57, instead including more sterically hindered 
 
40 
 
substituent groups. While the bulkiness of these groups may make the cyclization of the 
alcohol to the lactone too sterically hindered, cyclization could alternatively be aided by 
the bulk of the groups in Thorpe-Ingold effect and occur more easily.51 The potential 
angle compression caused by the bulky groups germinal to the alcohol group could 
position the alcohol even closer to the electrophilic carbonyl carbon, helping to overcome 
the steric barrier of the cyclization.51 
 
 
Figure 43. Planned Deprotection and Cyclization of Compound 77 
 
 
The targeted synthesis of compound 54 is another area which needs further 
development. The alternate alkylation sequence appears to produce desired product in 
higher yields while eliminating premature cyclization. This approach will be scaled up 
now that its benefits have been established, leading to a substantial increase in lactone 
products for further reaction. The monocyclic 77 will be converted to the spirocycle 54 
through a deprotection and achiral cyclization as detailed in Figure 43. The modification 
of compounds 54 and 77 to compound 79 will be done as detailed in Figure 38. 
Alternatively, the idea of reaction monitoring through NMR has been suggested and may 
provide more immediate insight into the reaction pathway. If the secondary cyclization 
reaction is slow enough to be monitored by NMR, the differences in 1H NMR should 
indicate the reaction pathway. The sets of vicinal hydrogens to the two nucleophilic 
oxygens have distinct peaks from one another, in addition to the shift difference between 
the cyclized and uncyclized forms of each. Using this information, it should be clear 
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whether the cyclized vicinal hydrogens are being altered by ring opening. This approach 
has yet to be attempted and highly depends on the reaction rate for the second 
cyclization, but if applicable it would eliminate the need for lengthy synthesis while 
providing the same insight.      
3.5 Conclusion 
 This chapter has shown the progress made towards the completion of a more 
extensive spirocyclic substrate scope and the targeted synthesis to understand the 
mechanism pathway. Continued work on these targets is already underway, including 
the preliminary synthesis of new alkylating agents. Despite some synthetic issues, both 
in the synthesis of compounds produced previously in the group and novel substrates, 
the overall desymmetrization strategy remains effective.     
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CHAPTER IV 
EXPERIMENTAL 
 
4.1 General Information 
 Unless otherwise noted, all reagents and solvents were acquired from 
commercial sources and used without additional purification. Anhydrous solvents were 
dried via standard procedures. The 1H and 13C nuclear magnetic resonance (NMR) 
spectra were obtained through use of a 400 MHz or 500 MHz spectrometer using 
chloroform-d or acetone-d6 at room temperature. The NMR chemical shifts (δ) are 
reported in ppm. Abbreviations for 1H NMR splitting patterns: s = singlet, d = doublet, m 
= multiplet, t = triplet, q = quartet, quint = quintet, sept = septet. All reactions were 
monitored via thin layer chromatography (TLC) using silica G F254 precoated glass-
backed plates. Flash column chromatography was done using flash grade silica gel 
(particle size: 40-63 µm, 230 x 400 mesh).  
4.2 Synthesis of Compound 23 
 
 
Figure 44. Synthesis of Compound 23 
 
 
To a solution of crushed cis-1,2,3,6-tetrahydrophthalic anhydride pellets (1.00 g, 
6.57 mmol) in acetic acid (1.85 mL, 6.57 mmol) was added 10 drops of 1 M hydrochloric 
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acid dropwise, followed by an aliquot of water (9.27 mL). The reaction solution was 
stirred overnight after which time, the solvent was removed through rotary-evaporation to 
yield the pure product 23 as a white, powdery solid (1.11g, >99% yield). 1H NMR (400 
MHz, Acetone-d6) δ 5.62 (s, 2H), 3.00 (m, 2H), 2.54 (dd, J = 16.3, 5.3 Hz, 2H), 2.33 (dd, 
J = 16.4, 5.5 Hz, 2H); 13C NMR (101 MHz, Acetone-d6) δ 174.0, 125.3, 38.9, 25.9. 
4.3 Synthesis of Compounds 27-29       
 
 
Figure 45. Synthesis of Compounds 27-29 
 
 
To a flame dried 25 mL round bottom flask under Argon was added (±)-cis-4-
cyclohexene-1,2-dicarboxylic acid 23 (0.552 g, 3.24 mmol) and methanol (dry, 7.90 mL). 
An aliquot of concentrated sulfuric acid (5 M, 0.143 mL, 0.713 mmol) was added 
dropwise to the reaction solution before the flask was heated to 75°C with an oil bath. 
The flask was removed from the oil bath after overnight reaction and the solvent was 
removed using rotary-evaporation. Once most of the solvent was removed, the residue 
was transferred to a separatory funnel and rinsed with ethyl acetate (10 mL). The 
solution was washed with a saturated sodium bicarbonate solution (20 mL) and the 
aqueous layer was extracted with ethyl acetate (3 x10mL). The combined organic layers 
were washed with a saturated sodium chloride solution (20 mL) and dried with 
magnesium sulfate. The mixture was filtered and the resulting solution was condensed 
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using rotary-evaporation. The concentrated residue was purified using flash 
chromatography on silica gel (2% methanol in CH2Cl2) to yield dimethyl ester product 27 
as an oil (0.4531 g, 71% yield). 1H NMR (400 MHz, Chloroform-d) δ 5.63 (d, J = 3.0 Hz, 
2H), 3.65 (s, 6H), 3.01 (t, J = 5.3 Hz, 2H), 2.51 (dd, J = 15.6, 4.4 Hz, 2H), 2.31 (dd, J = 
15.4, 4.4 Hz, 2H); 13C NMR (101 MHz, Acetone-d6) δ 173.12, 125.07, 51.01, 39.29, 
25.61. 
Diethyl product (28): 1H NMR (400 MHz, Chloroform-d) δ 5.65 (s, 2H), 4.12 (qt, J = 7.1, 
3.4 Hz, 4H), 3.01 (t, J = 5.7 Hz, 2H), 2.52 (dd, J = 16.6, 6.0 Hz, 2H), 2.32 (dd, J = 16.4, 
6.1 Hz, 2H), 1.22 (t, J = 7.2 Hz, 6H); 13C NMR (101 MHz, Chloroform-d) δ 173.4, 125.3, 
60.7, 39.9, 25.8, 14.2.  
Diisopropyl product (29): 1H NMR (400 MHz, Chloroform-d) δ 5.65 (s, 2H), 5.00 (sept, J 
= 6.3 Hz, 2H), 2.97 (t, J = 5.3 Hz, 2H), 2.51 (dd, J = 16.5, 5.5 Hz, 2H), 2.30 (dd, J = 16.5, 
5.2 Hz, 2H), 1.20 (d, J = 6.3 Hz, 12H); 13C NMR (101 MHz, Chloroform-d) δ 172.9, 
125.3, 68.0, 39.9, 25.9, 21.9.   
4.4 Synthesis of Compound 30   
 
 
Figure 46. Synthesis of Compound 30 
 
 
A solution of (±)-cis-4-cyclohexene-1,2-dicarboxylic acid 23 (0.250 g, 1.47 mmol) 
in toluene (3.75 mL) was made in an oven-dried two-necked 25 mL round bottom flask 
under inert atmosphere. The flask was heated to 80oC with an oil bath and heated for 10 
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minutes before N,N-dimethylformamide di-tert-butyl acetal (1.80 g, 8.85 mmol) was 
added. The reaction flask was removed from the oil bath after 43 hours and transferred 
to a separatory funnel with ethyl acetate (10 mL). The reaction solution was washed with 
deionized water (20 mL), then the organic phase was washed with a saturated sodium 
bicarbonate solution (20 mL). The combined aqueous layers were extracted with ethyl 
acetate (2 x 10 mL) and the combined organic layers were washed with saturated 
sodium chloride solution (20 mL). The final organic phase was dried over magnesium 
sulfate, filtered, and concentrated by rotary-evaporation. The condensed residue was 
purified using flash chromatography on silica gel (10→15% diethyl ether in hexanes) to 
yield ditertbutyl product 30 (0.0875 g, 21% yield). 1H NMR (400 MHz, Acetone-d6) δ 5.59 
(t, J = 1.5 Hz, 2H), 2.85 (td, J = 6.4, 5.6, 2.0 Hz, 2H), 2.46 (ddd, J = 15.9, 6.5, 2.1 Hz, 
2H), 2.24 (ddd, J = 16.0, 6.5, 1.8 Hz, 2H), 1.39 (s, 18H); 13C NMR (101 MHz, Acetone-
d6) δ 172.1, 125.2, 79.6, 40.2, 27.4, 26.0.  
4.5 Synthesis of Compounds 31-32   
 
 
Figure 47. Synthesis of Compounds 31-32 
 
 
A solution of potassium permanganate (2.86 g, 18.1 mmol) in deionized water 
(13.90 mL) was made in a 50 mL round bottom flask and stirred at room temperature 
open to air for 1 hour. The flask was cooled to 2°C with an ice water bath before diester 
product 28 (1.296 g, 5.729 mmol) dissolved in acetone (3 mL) was added slowly to the 
solution. The reaction flask was removed from the ice bath once the addition was 
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completed and was left to stir at room temperature. After 3 hours of reaction, 3 M 
hydrochloric acid solution were slowly added to the flask until the reaction solution 
changed from viscous, dark purple to a clear liquid. The solution was transferred to a 
separatory funnel and extracted using 1:1 ethyl acetate/THF (15 mL). The aqueous layer 
was extracted with 1:1 ethyl acetate/THF (3 x 10 mL) and the combined organic layers 
were washed with saturated sodium chloride solution (20 mL), dried over magnesium 
sulfate, filtered, and condensed by rotary evaporation to yield ring opened product 31 as 
a white solid (1.570 g, 94% yield). 
Ethyl ester (31): 1H NMR (400 MHz, Acetone-d6) δ 4.09 (qq, J = 10.6, 7.0 Hz, 4H), 3.06 
(m, 2H), 2.71 (dd, J = 17.3, 10.0 Hz, 1H), 2.51 (dd, J = 17.2, 3.9 Hz, 2H), 1.19 (t, J = 7.2 
Hz, 6H); 13C NMR (101 MHz, Acetone-d6) δ 172.1, 172.0, 60.6, 42.3, 32.3, 13.6. 
Isopropyl ester (32): 1H NMR (400 MHz, Acetone-d6) δ 4.94 (sept, J = 6.3 Hz, 2H), 3.23 
(m, 2H), 2.71 (dd, J = 17.0, 10.1 Hz, 2H), 2.48 (m, 2H), 1.20 (d, J = 3.7 Hz, 6H), 1.18 (d, 
J = 3.9 Hz, 6H); 13C NMR (101 MHz, Acetone-d6) δ 172.17, 171.5, 68.1, 42.3, 32.3, 21.1. 
4.6 Synthesis of Compounds 33-34  
 
 
Figure 48. Synthesis of Compounds 33-34 
 
 
A solution of ring opened product 31 (1.36 g, 4.70 mmol) in acetic anhydride 
(6.82 mL) was prepared in a flame-dried 25 mL two-necked round bottom flask under 
inert atmosphere. The reaction flask was heated to 130°C with a oil bath and stirred for 
1.5 hours. Acetic acid sodium salt (0.341 g, 4.153 mmol) was then added and the 
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mixture was stirred for several additional minutes before the flask was removed from the 
oil bath. Once the flask had cooled to room temperature it was cooled to 2°C in an ice 
bath and methanol (1 mL) was slowly added, followed by deionized water (2 mL). 
Sodium bicarbonate (0.454 g, 5.403 mmol) was added to the reaction solution after 
several minutes of stirring, resulting in bubbling of the solution. Once the bubbling had 
ceased, the solution was transferred to a separatory funnel and and extracted with 
dichloromethane (10 mL). The aqueous layer was washed with dichloromethane (2 x 10 
mL) , the organic layers were combined, and the combined layers were washed with 
saturated sodium chloride solution (20 mL). The resulting organic layer was dried over 
magnesium sulfate, filtered, and condensed by rotary evaporation. The residue was 
purified using flash chromatography on silica gel (50→60% diethyl ether in hexanes) to 
yield ketone cyclized product 33 as an oil (0.5572 g, 52% yield). 
Ethyl ester (33): 1H NMR (400 MHz, Acetone-d6) δ 4.08 (q, J = 7.2 Hz, 4H), 3.53 (m, 
2H), 2.50 (m, 4H), 1.19 (t, J = 7.1 Hz, 6H); 13C NMR (101 MHz, Acetone-d6) δ 212.7, 
172.4, 60.5, 43.2, 40.0, 13.6. 
Isopropyl ester (34): 1H NMR (400 MHz, Acetone-d6) δ 4.92 (sept, J = 6.4 Hz, 2H), 3.46 
(m, 2H), 2.48 (m, 4H), 1.19 (d, J = 2.0 Hz, 6H), 1.18 (d, J = 2.2 Hz, 6H); 13C NMR (101 
MHz, Acetone-d6) δ 212.8, 171.8, 68.0, 43.3, 40.2, 21.1. 
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4.7 Synthesis of Compound 35   
 
 
Figure 49. Synthesis of Compound 35 
 
 
A solution of cyclized ketone product 33 (0.555 g, 2.431 mmol) in ethanol (29.9 
mL) was made in a flame-dried 10 mL round bottom flask and put under inert 
atmosphere. The solution was cooled to 5°C with an ice water bath and stirred for 
several minutes before sodium borohydride (0.109 g, 2.893 mmol) was added. After 
stirring the reaction solution for an hour in the ice water bath, saturated sodium chloride 
solution (15 mL) was added to the round bottom flask and the solution was stirred for 
several minutes. The reaction solution was filtered to remove sodium chloride precipitate 
and the filtered solution was dried over magnesium sulfate, filtered, and concentrated by 
rotary evaporation. The condensed residue was purified by flash column 
chromatography on silica gel (50→100% diethyl ether in hexanes) yielding alcohol 
product 35 (0.382 g, 69% yield). 1H NMR (400 MHz, Acetone-d6) δ 4.21 (q, J = 6.6 Hz, 
1H), 4.03 (q, J = 7.2 Hz, 4H), 3.02 (td, J = 5.7, 2.9 Hz, 2H), 2.20 (m, 2H), 1.89 (m, 2H), 
1.16 (t, J = 7.2 Hz, 6H); 13C NMR (101 MHz, Acetone-d6) δ 173.4, 71.2, 60.0, 44.4, 38.0, 
13.7.    
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4.8 Synthesis of Compound 62   
 4.8.1 Tosylated Intermediate 61 
 
 
Figure 50. Tosylation to Intermediate 61 
 
 
To a flame-dried 10 mL round bottom flask was added 2,2-dimethyl-1,3-
propanediol (60) (0.200 g, 1.920 mmol), pyridine (0.110 mL, 1.36 mmol), and 
dichloromethane (0.645 mL). The solution was stirred for several minutes at room 
temperature before the flask was cooled with a 10°C ice water bath. An additional flame-
dried 10 mL round bottom flask under inert atmosphere was charged with 4-
toluenesulfonyl chloride (0.074 g, 0.386 mmol) and dichloromethane (0.386 mL). The 
flask containing dimethyl diol was removed from the ice water bath and replaced with the 
second flask before the diol solution was transferred slowly via syringe to the 4-
toluenesulfonyl chloride solution. The resulting reaction solution was stirred in the ice 
water bath. After 3 hours, the flask was removed and an aliquot of ethyl acetate (5 mL) 
was added to the reaction solution and stirred before the solution was transferred to a 
separatory funnel. Additional ethyl acetate was added (5 mL) and the reaction solution 
was washed with saturated sodium bicarbonate solution (20 mL). The aqueous layer 
was extracted with ethyl acetate (3 x 10 mL), the organic layers were combined, washed 
with saturated sodium chloride solution (20 mL), dried over magnesium sulfate, filtered, 
and finally condensed through rotary evaporation. The concentrated residue was purified 
by flash column chromatography on silica gel (20→40% ethyl acetate in hexanes) to 
 
50 
 
yield tosylated product 61 as an oil (0.0832 g, 88% yield). 1H NMR (400 MHz, Acetone-
d6) δ 7.77 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 3.81 (s, 2H), 3.26 (d, J = 4.0 Hz, 
2H), 2.89 (s, 1H), 2.42 (s, 3H), 0.81 (s, 6H); 13C NMR (101 MHz, Acetone-d6) δ 144.9, 
133.4, 130.0, 127.9, 75.6, 67.0, 36.3, 20.7, 20.5. 
 4.8.2 Compound 62  
 
 
Figure 51. Acetylation to Compound 62 
 
 
A solution of tosylated product 61 (0.0939 g, 0.363 mmol) in dichloromethane 
(2.42 mL) was made in a flame-dried 10 mL round bottom flask under inert atmosphere. 
After stirring for several minutes at room temperature, 4-dimethylaminopyridine (0.0021 
g, 0.0174 mmol), triethylamine (0.051 mL, 0.367 mmol), and acetic anhydride (0.058 mL, 
0.617 mmol) were added to the reaction flask and the solution was stirred. An addition of 
sodium bicarbonate (0.0096 g, 0.115 mmol) was made to the flask after 5 hours, 
followed by saturated sodium bicarbonate solution (1 mL). The solution was transferred 
to a separatory funnel, extracted using diethyl ether (10 mL), and washed with saturated 
sodium bicarbonate solution (20 mL). The aqueous layer was extracted with diethyl ether 
(2 x 10 mL) and the combined organic layers were washed with saturated sodium 
chloride solution (20 mL), dried over magnesium sulfate, and filtered. After concentration 
by rotary evaporation, the acetylated product 62 remained as an oil (0.0996 g, 91% 
yield). 1H NMR (500 MHz, Acetone-d6) δ 7.78 (d, J = 8.6 Hz, 2H), 7.47 (d, J = 7.4 Hz, 
 
51 
 
2H), 3.81 (s, 2H), 3.75 (s, 2H), 2.44 (s, 3H), 1.87 (s, 3H), 0.89 (s, 6H); 13C NMR (126 
MHz, Acetone-d6) δ 169.8, 145.1, 133.1, 130.1, 128.0, 74.6, 67.8, 34.8, 20.7, 20.6, 20.6. 
4.9 Synthesis of Compound 69 
 4.9.1 Initial Reaction Sequence to Synthesize Compound 69  
 
 
Figure 52. Initial Reaction Sequence to Synthesize Compound 69 
 
 
A solution of dimethyl diol 60 (0.200 g, 1.92 mmol) in dichloromethane (4.0 mL) 
was prepared in a flame-dried 10 mL round bottom flask. The flask was cooled with a -
5oC dry ice and isopropanol bath before pyridine (0.311 mL, 3.84 mmol) was added, 
followed by the dropwise addition of methylsulfonyl chloride (0.149 mL, 1.92 mmol).  
After 4 hours at 0°C, the reaction solution was diluted with ethyl acetate, transferred to a 
separatory funnel, and washed with saturated sodium bicarbonate solution (2 x 10 mL). 
The aqueous layer was extracted with ethyl acetate (2 x 10 mL) and the combined 
organic phases were washed with saturated sodium chloride solution (20 mL). The final 
organic phase was dried over magnesium sulfate, filtered, and condensed by rotary 
evaporation. The concentrated residue was purified by flash column chromatography on 
silica gel (20→100% ethyl acetate, 0.1% triethylamine in hexanes) but side products 
could not be completely removed to obtain an accurate yield. The crude mesylated 
product 68 was obtained (0.3835 g, crude >99% yield). 
In a flame-dried 25 mL round bottom flask was prepared a solution of mesylated 
dimethyl 68 (0.384 g, 2.10 mmol) in dichloromethane (14.0 mL), to which 4-
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dimethylaminopyridine (0.0123 g, 0.101 mmol), triethylamine (0.295 mL, 2.12 mmol), 
and acetic anhydride (0.337 mL, 3.57 mmol) were added. The reaction solution was 
stirred at room temperature. After 5 hours, sodium bicarbonate (0.0558 g, 0.664 mmol) 
was added to the solution along with saturated sodium bicarbonate solution (2 mL). 
Once this had stirred for 10 minutes, the solution was diluted with diethyl ether, 
transferred to a separatory funnel, and washed with saturated sodium bicarbonate (20 
mL). The aqueous layer was extracted using diethyl ether (2 x 10 mL) and the combined 
organic phases were washed with saturated sodium chloride solution (20 mL). The 
resulting organic layer was dried over magnesium sulfate, filtered, and condensed by 
rotary evaporation. The concentrated residue was purified by flash column 
chromatography on silica gel (25→75% ethyl acetate, 0.1% triethylamine in hexanes) to 
yield acetylated product 69 (0.1586 g, overall 37% yield). 1H NMR (400 MHz, Acetone-
d6) δ 4.01 (s, 2H), 3.86 (s, 2H), 3.08 (s, 3H), 2.00 (s, 3H), 0.98 (s, 6H); 13C NMR (101 
MHz, Acetone-d6) δ 170.1, 74.4, 68.0, 36.0, 34.9, 20.6, 19.8. 
 4.9.2 Alternative Sequence for Synthesis of Compound 69 
  
 
Figure 53. Alternative Sequence for Synthesis of Compound 69 
 
 
  In a flame-dried 50 mL round bottom flask was made a solution of dimethyl diol 
60 (0.3000 g, 2.88 mmol) in dichloromethane (19 mL), to which 4-dimethylaminopyridine 
(0.0169 g, 0.138 mmol), triethylamine (0.401 mL, 2.88 mmol), and acetic anhydride 
(0.272 mL, 2.88 mmol) were added. The reaction solution was stirred at room 
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temperature. After 6 hours, sodium bicarbonate (0.0760 g, 0.910 mmol) was added to 
the solution, along with saturated sodium bicarbonate solution (3 mL). Once this had 
stirred for 10 minutes, the solution was diluted with diethyl ether, then transferred to a 
separatory funnel and washed with saturated sodium bicarbonate (20 mL). The aqueous 
layer was extracted using diethyl ether (2 x 10 mL) and the combined organic phases 
were washed with saturated sodium chloride solution (20 mL). The resulting organic 
layer was dried over magnesium sulfate, filtered, and condensed by rotary evaporation. 
The concentrated residue was purified by flash column chromatography on silica gel 
(30→75% ethyl acetate, in hexanes) to yield acetylated product 70 (0.2157 g, 51% 
yield).  
  A solution of acetylated product 70 (0.100 g, 0.684 mmol) in dichloromethane 
(1.5 mL) was prepared in a flame-dried 10 mL round bottom flask. The flask was cooled 
with a -5oC dry ice and isopropanol bath before pyridine (0.111 mL, 1.368 mmol) was 
added, followed by the dropwise addition of methylsulfonyl chloride (0.089 mL, 1.163 
mmol). After 4 hours at 0°, the reaction solution was diluted with ethyl acetate (5 mL), 
transferred to a separatory funnel, and washed with saturated sodium bicarbonate 
solution (2 x 10 mL). The aqueous layer was extracted with ethyl acetate (2 x 10 mL) 
and the combined organic phases were washed with saturated sodium chloride solution 
(20 mL). The final organic phase was dried over magnesium sulfate, filtered, and 
condensed by rotary evaporation. The concentrated crude residue of product 69 was 
obtained (0.1450 g, crude 95% yield). 1H NMR (400 MHz, Acetone-d6) δ 4.01 (s, 2H), 
3.86 (s, 2H), 3.08 (s, 3H), 2.00 (s, 3H), 0.98 (s, 6H). 
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 4.9.3 Acetylated Intermediate 70 through Alternative Protocol  
 
 
Figure 54. Acetylation to Intermediate 70 through Alternative Protocol 
 
 
To a flame-dried 10 mL round bottom flask was added p-toluenesulfonic acid 
(monohydrate, 0.0006 g, 0.003 mmol) and dichloromethane (6.10 mL), followed by 
dimethyl diol 60 (0.500 g, 4.80 mmol). The solution was heated to 35oC before the diol 
was fully dissolved. Trimethyl orthoacetate (0.983 mL, 7.20 mmol) was added once the 
diol dissolved, then reaction solution was stirred at room temperature. After 1 hour, 
triethylamine (0.07 mL) was added to quench the reaction solution and stirred for several 
minutes before the solution was condensed through rotary evaporation. The resulting 
residue was returned to inert atmosphere and acetic acid (1.50 mL) was added. This 
solution was stirred at room temperature for 30 minutes. The reaction solution was then 
diluted with dichloromethane (10 mL), added to a separatory funnel, and washed with 
saturated sodium bicarbonate solution (2 x 10 mL). The combined aqueous layers were 
extracted with dichloromethane (2 x 10 mL), then the combined organic phases were 
washed with saturated sodium chloride solution (20 mL). The organic phase was dried 
over magnesium sulfate, filtered, and condensed by rotary evaporation. Analysis of the 
13C and 1H NMR spectra showed very little contamination and so no purification was 
required (0.4781 g, 68% yield). 1H NMR (400 MHz, Acetone-d6) δ 3.83 (s, 2H), 3.68 (t, J 
= 5.7 Hz, 1H), 3.29 (d, J = 5.7 Hz, 2H), 1.97 (s, 3H), 0.86 (s, 6H); 13C NMR (101 MHz, 
Acetone-d6) δ 170.4, 69.1, 67.5, 35.9, 20.9, 19.9. 
 
55 
 
 4.9.4 Mesylation of Alternate Protocol Product to Compound 69 
 
 
Figure 55. Mesylation of Alternate Protocol Product to Compound 69 
 
 
  A solution of acetylated compound 66 (0.478 g, 3.27 mmol) in dichloromethane 
(6.8 mL) was made in a flame-dried 15 mL round bottom flask. The flask was cooled to 
2oC with an ice and water bath before pyridine (0.661 mL, 8.18 mmol) was added, 
followed by the dropwise addition of methylsulfonyl chloride (0.633 mL, 8.18 mmol). After 
5 hours at 2°C, the reaction solution was diluted with ethyl acetate, transferred to a 
separatory funnel, and washed with saturated sodium bicarbonate solution (10 mL). The 
aqueous layer was extracted with ethyl acetate (2 x 10 mL) and the combined organic 
phases were washed with saturated sodium chloride solution (20 mL). The final organic 
phase was dried over magnesium sulfate, filtered, and condensed by rotary evaporation. 
The crude residue of product 65 was collected. 1H NMR (400 MHz, Acetone-d6) δ 4.01 
(s, 2H), 3.86 (s, 2H), 3.08 (s, 3H), 2.01 (s, 3H), 0.98 (s, 6H); 13C NMR (101 MHz, 
Acetone-d6) δ 170.1, 74.4, 68.0, 36.0, 34.9, 20.6, 19.8.  
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4.10 Synthesis of Compound 73    
 
 
Figure 56. Synthesis of Compound 73 
 
 
To a flame-dried 10 mL round bottom flask was added p-toluenesulfonic acid 
(monohydrate, 0.0004 g, 0.002 mmol) and dichloromethane (3.72 mL), followed by 
cyclopropyl diol 71 (0.282 mL, 2.94 mmol) and trimethyl orthoacetate (0.602 mL, 4.41 
mmol). The reaction solution was stirred at room temperature. After 1 hour, triethylamine 
(0.04 mL) was added to quench the reaction solution and stirred for several minutes 
before the solution was condensed through rotary evaporation. The resulting residue 
was returned to inert atmosphere and acetic acid (0.925 mL) was added. This solution 
was stirred at room temperature for 30 minutes. The reaction solution was then diluted 
with dichloromethane (10 mL) , added to a separatory funnel, and washed with saturated 
sodium bicarbonate solution (2 x 10 mL). The combined aqueous layers were extracted 
with dichloromethane (2 x 10 mL), then the combined organic phases were washed with 
saturated sodium chloride solution (20 mL). The final organic phase was dried over 
magnesium sulfate, filtered, and condensed by rotary evaporation. The residue was 
purified by flash column chromatography on silica gel (10→45% ethyl acetate in 
hexanes) to yield acylated product 72 (0.3190 g, 75% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 4.02 (s, 2H), 3.42 (s, 2H), 2.07 (s, 3H), 0.53 (m, 4H);13C NMR (101 
MHz, Chloroform-d) δ 171.8, 68.5, 66.8, 22.4, 21.1, 9.0.   
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A solution of acetylated compound 72 (0.100 g, 0.694 mmol) in dichloromethane 
(1.5 mL) was prepared in a flame-dried 10 mL round bottom flask. The flask was cooled 
to 0oC with an ice and water bath before pyridine (0.168 mL, 2.08 mmol) was added, 
followed by the dropwise addition of methylsulfonyl chloride (0.161 mL, 2.08 mmol). After 
5 hours, the reaction solution was diluted with ethyl acetate, transferred to a separatory 
funnel, and washed with saturated sodium bicarbonate solution (10 mL). The aqueous 
layer was extracted with ethyl acetate (2 x 10 mL) and the combined organic phases 
were washed with saturated sodium chloride solution (20 mL). The final organic phase 
was dried over magnesium sulfate, filtered, and condensed by rotary evaporation. The 
crude residue was collected and used for the alkylation attempt (crude 0.2055 g, >99% 
yield). 1H NMR (400 MHz, Acetone-d6) δ 4.13 (s, 2H), 3.98 (s, 2H), 3.07 (s, 3H), 2.00 (s, 
3H), 0.70 (s, 4H); 13C NMR (126 MHz, Chloroform-d) δ 171.1, 67.3, 66.0, 37.7, 21.0, 
19.9, 10.0. 
4.11 Synthesis of Compound 53  
 4.11.1 Dialkylated Intermediate 76 
 
 
Figure 57. Synthesis of Dialkylated Intermediate 76 
 
 
To a flame-dried 25 mL round bottom was added sodium hydride (60% in mineral 
oil, 0.278g, 6.90 mmol) and tetrahydrofuran (16.40 mL). After stirring for several minutes, 
di-tert-butyl malonate (1.55 mL, 6.90 mmol) was added dropwise to the flask. The 
solution stirred for about 10 minutes before the bubbling ceased and appearance 
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became less cloudy, then benzyl 2-bromoethylether (1.10 mL, 6.90 mmol) was added 
dropwise. The reaction flask was heated to 60°C with an oil bath and stirred. After 27 
hours, the flask was removed from the oil bath and saturated ammonium chloride 
solution was added until bubbling upon addition ceased. The reaction solution was 
transferred to a separatory funnel and deionized water (10 mL) was added. The resulting 
organic phase was washed with deionized water (2 x 10 mL), then saturated sodium 
chloride solution (10 mL) before being collected. The combined aqueous phases were 
extracted with diethyl ether (2 x 10 mL) and each organic phase was washed with 
sodium chloride solution (10 mL) before the combined organic layers were washed with 
sodium chloride solution (20 mL), dried over magnesium sulfate, filtered, and condensed 
by rotary evaporation. The concentrated residue was purified by flash column 
chromatography on silica gel (5→25% ethyl acetate in hexanes) yielding the 
monoalkylated intermediate (1.7428 g, 72% yield). 
A solution of sodium hydride (60% in mineral oil, 0.382 g, 9.56 mmol) in 
tetrahydrofuran (6.37 mL) was made in a flame-dried 25 mL round bottom flask. The 
solution was stirred for several minutes before the monoalkylated product (1.67 g, 4.78 
mmol) dissolved in tetrahydrofuran (3.68 mL) was added to it and the flask was cooled to 
2°C with an ice water bath. Once bubbling of the solution was no longer seen, N-tosyl 
aziridine (0.804 g, 4.08 mmol) dissolved in tetrahydrofuran (4.21 mL) was slowly added 
and stirred. After 46 hours, the flask was removed from the room temperature water bath 
and saturated ammonium chloride solution was added to the reaction solution until 
bubbling ceased. The solution was transferred to a separatory funnel and washed with 
deionized water (10 mL). The organic phase was washed with deionized water (2 x 10 
mL) then saturated sodium chloride solution (10 mL) before being collected. The 
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combined aqueous layers were extracted with diethyl ether (2 x 10 mL) and each 
organic layer was washed with sodium chloride solution collection. The combined 
organic layers were washed with sodium chloride solution (20 mL) and the resulting 
organic layer was dried over magnesium sulfate, filtered, and condensed by rotary 
evaporation. The concentrated residue was purified by flash column chromatography on 
silica gel (20→100% ethyl acetate in hexanes) yielding dialkylated product 76 (1.3432 g, 
51% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.63 (m, 2H), 7.31 (m, 6H), 7.23 (s, 1H), 
4.75 (t, J = 5.9 Hz, 1H), 4.40 (s, 2H), 3.38 (t, J = 6.4 Hz, 2H), 2.89 (td, J = 7.3, 6.0 Hz, 
2H), 2.39 (s, 3H), 2.09 (t, J = 6.4 Hz, 2H), 2.02 (t, J = 7.3 Hz, 2H), 1.37 (s, 18H); 13C 
NMR (101 MHz, Chloroform-d) δ 170.2, 143.3, 137.9, 136.8, 129.7, 128.5, 128.0, 127.9, 
127.2, 82.0, 73.3, 66.1, 56.5, 39.3, 32.4, 27.8, 21.6, 21.2.  
4.11.2 Debenzylated intermediate 74  
 
 
Figure 58. Synthesis of Debenzylated Intermediate 74 
 
 
To a flame-dried 25 mL round bottom flask was added a solution of dialkylated 
product 76 (0.484 g, 0.884 mmol) in ethyl acetate (17.7 mL), followed by palladium 
hydroxide on carbon (0.0620 g, 0.442 mmol). Hydrogen gas was flushed through the 
flask two times by evacuation of the gas with the house vacuum, then the third balloon 
was used to keep the reaction under hydrogen gas for its duration. The solution was 
stirred at room temperature overnight, after which time the hydrogen gas was removed 
from the flask using the house vacuum. The solution was then filtered through celite and 
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rinsed with ethyl acetate (20 mL). The filtered solution was analyzed using gas 
chromatography and showed only about 50% conversion to product. The solution was 
condensed by rotary evaporation, added to a new flame-dried 25 mL round bottom flask, 
and the same portions of palladium hydroxide on carbon and ethyl acetate were added. 
The flask was once again flushed twice with hydrogen gas before. Following another 24 
hour reaction the solution filtered through celite and gas chromatography analysis 
showed nearly complete conversion. The solution was again condensed through rotary 
evaporation and the residue was purified by flash column chromatography on silica gel 
(25→75% ethyl acetate in hexanes) yielding debenzylated product 74 as a white solid 
(0.1777 g, 44% yield). 1H NMR (400 MHz, Acetone-d6) δ 7.70 (d, J = 8.2 Hz, 2H), 7.37 
(d, J = 8.1 Hz, 2H), 6.43 (t, J = 6.2 Hz, 1H), 3.58 (t, J = 5.2 Hz, 1H), 3.48 (q, J = 6.5 Hz, 
2H), 2.83 (m, 4H), 2.39 (s, 3H), 1.95 (t, J = 7.1 Hz, 2H), 1.37 (s, 18H); 13C NMR (101 
MHz, Acetone-d6) δ 169.9, 168.9, 147.1, 133.6, 129.6, 127.0, 80.9, 55.7, 52.7, 49.2, 
43.8, 34.96, 27.1, 20.5.   
4.11.3 Enantioenriched Monocyclized Intermediate 75  
 
 
Figure 59. Synthesis of Enantioenriched Monocyclized Intermediate 75 
 
 
To a flame-dried 25 mL round bottom flask was added debenzylated product 74 
(0.548g, 1.20 mmol) dissolved in dichloroethane (12 mL). S-TRIP catalyst (0.045 g, 
0.060 mmol) was added and the solution was stirred at room temperature. After 7 days,  
the round bottom solution was diluted with ethyl acetate (10 mL), transferred to a 
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separatory funnel, and washed with deionized water (2 x 10 mL). The aqueous layer was 
extracted with ethyl acetate (10 mL) and the combined organic phases were washed 
with saturated sodium chloride solution (20 mL). The resulting organic layer was dried 
over magnesium sulfate, filtered, and condensed by rotary evaporation. The 
concentrated residue was purified by flash column chromatography on silica gel 
(30→50% ethyl acetate in hexanes) to give monocyclic product 75 (0.1589 g, 35% 
yield). 1H NMR (500 MHz, Acetone-d6) δ 7.71 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.0 Hz, 
2H), 4.30 (m, 2H), 3.09 (ddt, J = 12.7, 9.9, 5.7 Hz, 1H), 2.92 (ddt, J = 12.4, 10.0, 6.1 Hz, 
1H), 2.63 (ddd, J = 13.3, 7.0, 3.1 Hz, 1H), 2.34 (dt, J = 13.2, 8.9 Hz, 1H), 2.17 (ddd, J = 
13.9, 9.9, 5.5 Hz, 1H), 1.90 (ddd, J = 13.8, 10.1, 6.0 Hz, 1H), 1.39 (s, 9H); 13C NMR (126 
MHz, Acetone-d6) δ 174.6, 168.4, 143.1, 137.9, 129.7, 127.0, 82.5, 66.3, 53.3, 39.4, 
33.6, 32.0, 27.0, 20.6. 
4.11.4 Compound 53  
 
 
Figure 60. Cyclization to Compound 53 
 
 
In a flame-dried 15 mL round bottom flask was made a solution of monocyclic 
product 75 (0.158 g, 0.412 mmol) in dichloromethane (5.10 mL). To this solution 
trifluoroacetic acid (5.89 mL, 76.9 mmol) was added slowly before the solution was 
stirred at room temperature. After 47 hours, ethyl acetate (10 mL) was added to the 
reaction solution and the flask contents were transferred to a separatory funnel. The 
solution was washed with deionized water (20 mL), the aqueous layer was extracted 
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with ethyl acetate (2 x 10 mL), and the combined organic phases were washed with 
saturated sodium chloride solution (20 mL). The final organic layer was dried over 
magnesium sulfate, filtered, and condensed by rotary evaporation. The crude spirocyclic 
product 53 was collected (0.1153 g, 90% crude yield). 1H NMR (500 MHz, Chloroform-d) 
δ 7.89 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.49 (dd, J = 16.5, 8.2 Hz, 1H), 4.32 
(td, J = 8.7, 4.1 Hz, 1H), 4.04 (m, 2H), 2.73 (ddd, J = 13.0, 7.5, 4.1 Hz, 1H), 2.54 (ddd, J 
= 13.0, 6.8, 3.0 Hz, 1H), 2.43 (s, 3H), 2.18 (m, 2H); 13C NMR (126 MHz, Chloroform-d) δ 
174.3, 170.1, 145.9, 134.2, 129.9, 128.2, 66.8, 53.0, 45.0, 32.1, 28.8, 21.9. 
4.12 Synthesis of Compound 77   
 4.12.1 Dialkylated intermediate 80 
 
 
Figure 61. Synthesis of Dialkylated Intermediate 80 
 
 
A solution of sodium hydride (60% in mineral oil, 0.185 g, 4.62 mmol) in 
tetrahydrofuran (28 mL) was prepared in a flame-dried 50 mL round bottom flask under 
inert atmosphere and allowed to stir for several minutes. Di-tert-butyl malonate (1.00 g, 
4.62 mmol) was added to the reaction flask dropwise and the solution was stirred at 
room temperature until the solution ceased bubbling and turned from cloudy to 
transparent. Once this change was observed, ethyl bromoacetate (0.501 mL, 4.62 mmol) 
was added dropwise to the flask and the reaction solution was stirred. After 3 days, 
saturated ammonium chloride solution was added to the flask until bubbling could no 
longer be seen and stirred for several minutes until the solution became transparent. 
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The solution was then transferred to a separatory funnel and deionized water (10mL) 
was added. The organic phase was washed with deionized water (2 x 10 mL) and 
saturated sodium chloride solution (10 mL). The combined aqueous layers were 
extracted with diethyl ether (2 x 10 mL) and each organic phase was washed with 
saturated sodium chloride solution (10 mL) before collection. The combined organic 
layers were washed with saturated sodium chloride solution (20 mL), dried over 
magnesium sulfate, and concentrated via rotary evaporation. The condensed residue 
was purified by flash column chromatography on silica gel (5→30% ethyl acetate in 
hexanes) to yield monoalkylated intermediate (0.8870 g, 64% yield). 
Into a 10 mL flame-dried round bottom flask was added sodium hydride (60% in 
mineral oil, 0.0670 g, 1.69 mmol) and tetrahydrofuran (4.00 mL). Previously synthesized 
monoalkylated product (0.255 g, 0.843 mmol) was dissolved in tetrahydrofuran (2.00 
mL) and added to the flask slowly. After the solution had ceased bubbling and become 
more transparent, benzyl-3-bromopropylether (0.149 mL, 0.843 mmol) was added slowly 
to the reaction solution before the flask was heated with a 55oC oil bath. After 3 days, the 
flask was removed from the oil bath and saturated ammonium chloride solution (4 mL) 
was added to the reaction solution. After stirring for several minutes, the contents of the 
flask were transferred to a separatory funnel and additional ammonium chloride solution 
(10 mL) as well as deionized water (20 mL) were added. The resulting organic layer was 
washed with deionized water (2 x 10 mL) and then saturated sodium chloride solution 
(10 mL) before collection. The aqueous phase was extracted with diethyl ether (2 x 10 
mL), each extraction washed with sodium chloride solution (10 mL) before collection. 
The collected organic layers were washed with sodium chloride solution (20 mL), dried 
over magnesium sulfate, filtered, and condensed by rotary evaporation. The 
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concentrated residue was purified by flash column chromatography on silica gel 
(5→20% ethyl acetate in hexanes) to yield dialkylated product 80 (0.1632 g, 43% yield). 
1H NMR (400 MHz, Acetone-d6) δ 7.31 (m, 5H), 4.47 (s, 2H), 4.06 (t, J = 7.2 Hz, 2H), 
3.45 (t, J = 6.5 Hz, 2H), 2.16 (t, J = 7.2 Hz, 2H), 1.98 (s, 3H), 1.90 (m, 2H), 1.43 (s, 
18H);13C NMR (101 MHz, Chloroform-d) δ 171.0, 170.4, 138.6, 128.4, 127.7, 127.6, 
81.6, 72.9, 70.3, 60.8, 56.7, 30.7, 29.2, 28.0, 24.5, 21.0.  
 4.12.2 Alternative Alkylation Sequence to Compound 80 
  
 
Figure 62. Alternative Alkylation Sequence to Compound 80 
 
 
  Into a 10 mL flame-dried round bottom flask was added sodium hydride (60% in 
mineral oil, 0.0630 g, 1.58 mmol) and tetrahydrofuran (4.00 mL). Di-tert-butyl malonate 
(0.236 mL, 1.05 mmol) was added to the flask slowly. After the solution had ceased 
bubbling and become more transparent, benzyl-3-bromopropylether (0.250 mL, 1.58 
mmol) was added slowly to the reaction solution before the flask was heated with a 55oC 
oil bath. After 2 days, the flask was removed from the oil bath and saturated ammonium 
chloride solution (4 mL) was added to the reaction solution. After stirring for several 
minutes, the contents of the flask were transferred to a separatory funnel and additional 
ammonium chloride solution (10 mL) as well as deionized water (10 mL) were added. 
The resulting organic layer was washed with deionized water (2 x 10 mL), then with 
saturated sodium chloride solution (10 mL) before collection. The aqueous phase was 
extracted with diethyl ether (2 x 10 mL) and each extraction was washed with sodium 
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chloride solution (10 mL) before collection. The collected organic layers were washed 
with sodium chloride solution (20 mL), dried over magnesium sulfate, filtered, and 
condensed by rotary evaporation. The crude residue was collected (0.5425 g, >99% 
crude yield). 
  A solution of sodium hydride (60% in mineral oil, 0.149 g, 3.72 mmol) in 
dimethylformamide (9 mL) was made in a flame-dried 25 mL round bottom flask under 
inert atmosphere and stirred for several minutes. Previously synthesized monoalkylated 
product (0.543 g, 1.49 mmol) was added to the reaction flask slowly and the solution 
was stirred at room temperature until the solution ceased bubbling and turned from 
cloudy to transparent. After 30 min, ethyl bromoacetate (0.410 mL, 3.72 mmol) was 
added dropwise to the flask. After 2 days, saturated ammonium chloride solution was 
added to the flask until bubbling could no longer be seen and allowed to stir for several 
minutes until the solution became transparent. The solution was then transferred to a 
separatory funnel and deionized water (10mL) was added. The organic phase was 
washed with deionized water (2 x 10 mL) and saturated sodium chloride solution (10 mL) 
before being collected. The combined aqueous layers were extracted with diethyl ether 
(2 x 10 mL), washing each organic phase with saturated sodium chloride solution (10 
mL) before collection. The combined organic layers were washed with saturated sodium 
chloride solution (20 mL), dried over magnesium sulfate, and concentrated via rotary 
evaporation. Crude residue of product 80 was collected (0.6281 g, 93% crude yield).  
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4.12.3 Debenzylation and Cyclization to Compound 77  
 
 
Figure 63. Debenzylation and Enantioenriched Cyclization to Intermediate 77 
 
A solution of dialkylated product 80 (0.163 g, 0.362 mmol) in methanol (4.70 mL) 
was made in a flame-dried 10 mL round bottom flask before potassium carbonate (0.200 
g, 1.45 mmol) was added. Following the carbonate addition, the reaction solution was 
stirred at room temperature. After 35 minutes, the contents of the flask were transferred 
to a separatory funnel. Product was extracted with dichloromethane (10 mL) and washed 
with deionized water (20 mL). The aqueous layer was extracted with dichloromethane (2 
x 10 mL) and the organic phases were combined. The collected organic layers were 
washed with saturated sodium chloride solution (20 mL) before being dried over 
magnesium sulfate, filtered, and condensed through rotary evaporation to yield 
deprotected product 81 (0.1296 g, 88% yield).  
A solution of R-TRIP catalyst (0.012 g, 0.016 mmol) in dichloromethane (3.97 
mL) was made in a flame-dried 10 mL round bottom flask. Deprotected product 81 
(0.130 g, 0.317 mmol) was added slowly to the solution and the reaction was stirred at 
room temperature. After 7 days, ethyl acetate (10 mL) was added to the solution and it 
was washed with deionized water (20 mL). The aqueous layer was extracted with ethyl 
acetate (2 x 10 mL) and the organic layers were combined, washed with saturated 
sodium chloride solution (20 mL), then the resulting organic phase was dried over 
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magnesium sulfate. After being filtered, the solution was condensed through rotary 
evaporation. The condensed residue was purified by column chromatography on silica 
gel (15→50% ethyl acetate in hexanes) to yield monocyclized product 77 (0.0278 g, 
26% yield).  1H NMR (500 MHz, Chloroform-d) δ 7.32(m, 5H), 4.49 (s, 2H), 4.30 (dd, J = 
8.9, 5.2 Hz, 2H), 3.49 (td, J = 6.8, 6.2, 1.8 Hz, 2H), 2.65 (dt, J = 13.1, 4.8 Hz, 1H), 2.21 
(dt, J = 12.8, 9.0 Hz, 1H), 2.12 (ddd, J = 13.3, 12.2, 4.1 Hz, 1H), 1.83 (ddd, J = 13.4, 
12.1, 4.3 Hz, 1H), 1.75 (m, 1H), 1.58 (m, 1H), 1.46 (s, 9H); 13C NMR (126 MHz, 
Chloroform-d) δ 175.3, 168.7, 138.4, 135.9, 128.5, 127.8, 83.1, 73.0, 70.0, 66.2, 54.7, 
32.0, 27.9, 25.2, 22.9. 
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APPENDIX A 
NMR SPECTRA 
 
The 1H and 13C nuclear magnetic resonance (NMR) spectra were obtained via a 
JEOL 400 and 500 MHz spectrometer using chloroform-d or acetone-d6 as a solvent at 
room temperature. The NMR chemical shifts (δ) are reported in parts per million (ppm). 
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